New Report Just Published: World Multiple Myeloma Therapeutics Market Report
... Trial II-44 FDA Grants Approval for Use of VELCADE(R) for Patients with Mantle Cell Lymphoma II-44 4. Recent Industry Activity II-45 cytrx to Acquire Innovive II-45 Launch of Epoetin alfa Hexal II-45 PDL and Bristol-Myers Signs Agreement II-45 MNKD and LLS Conclude Joint Resea...CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
... LOS ANGELES--(BUSINESS WIRE)--Apr 4, 2007 - cytrx Corporation (NASDAQ:CYTR) today announced positive...firm and expand upon preclinical data announced by cytrx in December 2006. Orally-administered arimoclomol ...rig's disease). Based on these impressive results, cytrx will begin planning a potential Phase II clinical ...CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
... LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - cytrx Corporation (NASDAQ:CYTR), a biopharmaceutical com...hy volunteers with its drug candidate arimoclomol. cytrx believes that the results of this trial support th...n its previous Phase IIa clinical trials for ALS. cytrx plans to begin its Phase IIb clinical trial in the...CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
... LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - cytrx Corporation (NASDAQ:CYTR), a biopharmaceutical com...re of obesity). In the absence of placebo control, cytrx chose to compare the open-label clinical trial res...sly announced rising multiple dose clinical trial, cytrx plans to commence its Phase IIb clinical trial lat...